Improving influenza vaccines

Expert Review of Vaccines

Volumn 11, Issue 8, 2012, Pages 871-872

  Sambhara, Suryaprakash ^a   Rappuoli, Rino ^b  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; NEUTRALIZING ANTIBODY;

COMPLEMENT SYSTEM; CROSS PROTECTION; CROSS REACTION; CYTOTOXICITY; EDITORIAL; HUMAN; IMMUNOLOGY; IN VITRO STUDY; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; VACCINE PRODUCTION; VIRUS TRANSMISSION;

ANTIGENS, VIRAL; ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; ORTHOMYXOVIRIDAE; VACCINATION;

EID: 84866665202     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/erv.12.79     Document Type: Editorial

References (15)

1. Rowhani-Rahbar A, Klein NP, Baxter R. Assessing the safety of influenza vaccination in specific populations: children and the elderly. Expert Rev. Vaccines 11(8), 973-984 (2012).
2. Moro PL, Tepper NK, Grohskopf LA, Vellozzi C, Broder K. Safety of seasonal influenza and influenza A (H1N1) 2009 monovalent vaccines in pregnancy. Expert Rev. Vaccines 11(8), 911-921 (2012).
3. Bodewes R, Fraaij PLA, Osterhaus ADME, Rimmelzwaan GF. Pediatric influenza vaccination: understanding the T-cell response. Expert Rev. Vaccines 11(8), 963-971 (2012).
4. Schotsaert M, Saelens X, Leroux-Roels G. Influenza vaccines: T cell responses deserve more attention. Expert Rev. Vaccines 11(8), 949-962 (2012).
5. Lambert ND, Ovsyannikova IG, Pankratz VS, Jacobson RM, Poland GA. Understanding the immune response to seasonal influenza vaccination in older adults: a systems biology approach. Expert Rev. Vaccines 11(8), 985-994 (2012).
6. Kang S-M, Kim M-C, Compans RW. Viruslike particles as universal influenza vaccines. Expert Rev. Vaccines 11(8), 995-1007 (2012).
7. Rebmann T, Zelicoff A. Vaccination against influenza: role and limitations in pandemic intervention plans. Expert Rev. Vaccines 11(8), 1009-1019 (2012).
8. Neuzil KM, Tsvetnitsky V, Nyari LJ, Bright RA, Boslego JW. PATH Influenza Vaccine Project: accelerating the development of new influenza vaccines for low-resource countries. Expert Rev. Vaccines 11(8), 939-947 (2012).
9. Oxford JS, Oxford JR. Clinical, scientific and ethnographic studies of influenza in quarantine. Expert Rev. Vaccines 11(8), 929-937 (2012).
10. Shaw AR. Universal influenza vaccine, the holy grail? Expert Rev. Vaccines 11(8), 923-927 (2012).
11. Gilbert SC. Influenza vaccines and immunopathology. Expert Rev. Vaccines 11(8), 873-875 (2012).
12. Wagner R, Pfleiderer M. Reproducibility of assays for influenza vaccine immunogenicity determination: progress towards consistency. Expert Rev. Vaccines 11(8), 881-883 (2012).
13. Swayne DE. The role of vaccines and vaccination in high pathogenicity avian influenza control and eradication. Expert Rev. Vaccines 11(8), 877-880 (2012).
14. Tang DC. Perspectives on replicationincompetent nasal influenza virus vaccines. Expert Rev. Vaccines 11(8), 907-909 (2012).
15. Hisano M, Yamaguchi K. Usefulness of influenza vaccination during pregnancy to mothers and young infants. Expert Rev. Vaccines 11(8), 903-905 (2012).